Reckitt At '2.0' On Consumer Expansion But Question No. 1 Remains, Potential Pfizer Business Bid?
Executive Summary
UK firm sees acquisitions of Mead Johnson Nutrition and the Schiff brand as major milestones in its trajectory as a consumer health market competitor, but market analysts say both would be rendered comparatively minor moves if it makes an offer to acquire Pfizer's consumer products business.
You may also be interested in...
Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains
Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.
Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains
Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.
GSK’s Horlicks Review Plan - Some Early Expectations In India
A potential sale of Horlicks could impact market dynamics significantly in India where the popular malt beverage holds a dominant position but has seen competition build up. GlaxoSmithKline, though, has underscored that the review plan had nothing to do with the product’s "critical mass".